PedAM
Pediatric Disease Annotations & Medicines
| Disease | gout |
| Symptom | C0740394|hyperuricemia |
| Sentences | 41 |
| PubMedID- 20151160 | Mutations in the umod gene encoding uromodulin (tamm-horsfall glycoprotein) result in the autosomal dominant transmission of progressive renal insufficiency and hypo-uricosuric hyperuricemia leading to gout at an early age. |
| PubMedID- 24684266 | The fda approval of febuxostat for the treatment of hyperuricemia in gout has been a significant step forward. |
| PubMedID- 24055166 | Affected individuals have hyperuricemia leading to gout and urolithiasis, accompanied by a characteristic severe neurobehavioural phenotype with compulsive self-mutilation, extrapyramidal motor disturbances and cognitive impairment. |
| PubMedID- 20955624 | Background: increase in the incidence of hyperuricemia associated with gout as well as hypertension, renal diseases and cardiovascular diseases has been a public health concern. |
| PubMedID- 19909378 | Febuxostat, a non-purine xanthine-oxidase inhibitor, is a new agent approved for the treatment of hyperuricemia in patients with gout, which may be used when allopurinol is contraindicated. |
| PubMedID- 21170252 | This could result in accumulation of uric acid in blood (hyperuricemia) and tissues leading to visceral gout, which might be responsible for high mortality in birds. |
| PubMedID- 22000646 | Despite its potential advantage as an antioxidant, sustained hyperuricemia is associated with gout, renal diseases, hypertension, and cardiovascular diseases. |
| PubMedID- 26349049 | As a drug used to treat hyperuricemia associated with gout, tumor lysis syndrome, and the lesch-nyhan disease, urate oxidase (uox, also called uricase) is an enzyme of considerable biomedical interest123. |
| PubMedID- 21387258 | Dlts included grade 4 (according to national cancer institute common terminology criteria for adverse events version 3.0) hyperuricemia with grade 2 gout and grade 3 lipase associated with grade 2 pancreatitis at dose level 2, and grade 3 rash in 2 patients at dose level 3. |
| PubMedID- 22436129 | Febuxostat is a selective, novel, non-purine analog xo inhibitor . |
| PubMedID- 22359229 | Furthermore, hyperuricemia in gout is most commonly the result of relative urate underexcretion, as the kidney has enormous capacity for urate reabsorption. |
| PubMedID- 21353107 | Background: use of urate-lowering therapy (ult), such as febuxostat or allopurinol, is recommended for the long-term management of hyperuricemia in patients with gout to reduce the incidence of acute flares. |
| PubMedID- 24448692 | Topiroxostat (formerly known as fyx-051) is an orally administered non-purine analog, selective xanthine oxidase (xo) inhibitor developed for the management of hyperuricemia, including in patients with gout, in japan. |
| PubMedID- 23840514 | It is mainly used for the treatment of hyperuricemia in patients with gout or tumor lysis syndrome. |
| PubMedID- 25963969 | Until recently, the treatment of hyperuricemia in gout mostly hinged on the appropriate use of a single drug, that is, allopurinol, since the use of uricosurics is uncommon. |
| PubMedID- 22384520 | hyperuricemia with gout, isolated gout without hyperiuricemia or hyperuricemia without gout are conditions which require ordinarily monitoring. |
| PubMedID- 21898351 | Conclusion: our data support the hypothesis that after appropriate long-term treatment of hyperuricemia in gout with urate crystal dissolution being the therapeutic target, lifelong treatment can be targeted to achieve serum urate levels just below the threshold for saturation to avoid new crystal formation, similar to cleaning a dirty dish: more is required to get it clean than to keep it clean. |
| PubMedID- 20215410 | In this species, hyperuricemia is associated with gout, nephropathy, and increased cardiovascular disease risk. |
| PubMedID- 23762766 | hyperuricemia is associated with severe gout and kidney problems. |
| PubMedID- 22870483 | During the past few years two novel therapeutic agents have been approved by the us food and drug administration for the treatment of hyperuricemia in patients with gout, one of them being febuxostat, a nonpurine selective inhibitor of xanthine oxidase. |
| PubMedID- 26515421 | Recent epidemiological studies have indicated that hyperuricemia with or without gout increases the risk of cardiovascular diseases and mortality . |
| PubMedID- 25890021 | For example, previous studies showed that in the pathogenesis of hyperuricemia, apoe polymorphisms in patients with gout were reported to be associated with reduced renal excretion of urates . |
| PubMedID- 22606238 | However, clinical studies have yielded inconsistent results probably because it is important to target a specific population of patients with hf; for instance, patients with moderate-to severe hf that had elevated serum uric acid levels are most likely to benefit from allopurinol treatment, the cornerstone of the clinical management of gout and conditions associated with hyperuricemia for several decades . |
| PubMedID- 24732692 | The hypothetical cohort of 1,000 patients requiring allopurinol for preventing or treating gouty patients with hyperuricemia, and tophaceous gout was entered into the model. |
| PubMedID- 23137576 | The approval of new therapies to treat hyperuricemia in gout has led to a new understanding of gout management and medication safety regarding new and old therapies. |
| PubMedID- 25889813 | It was suggested that accumulation of visceral fat rather than subcutaneous fat is associated with metabolic abnormalities and hyperuricemia in patients with gout; therefore, we hypothesized that visceral fat accumulation was increased in non-obese gout patients. |
| PubMedID- 23112391 | The drugs available for the treatment of hyperuricemia in patients with gout are uricosuric agents (e.g. |
| PubMedID- 23738826 | A poor metabolic control may lead to long term complications, namely development of hepatocellular adenomas (hca), renal dysfunction, gout and nephrocalcinosis associated with hyperuricemia, and increased risk of pancreatitis, related to severe hypertrigliceridemia . |
| PubMedID- 24476385 | Of particular relevance to the current study is the observation that fructose-induced hyperuricemia is accentuated in patients with gout and first-degree relatives of patients with gout. |
| PubMedID- 22316106 | Febuxostat is a selective, non-purine analog xo inhibitor for the treatment of chronic hyperuricemia in patients with gout . |
| PubMedID- 20091036 | The hyperuricemia in gout might be caused by the increased adiposity associated with insulin resistance. |
| PubMedID- 23802027 | The observation of a significantly decreased giant cells in gout patients with hyperuricemia is of interesting, but need further confirmation. |
| PubMedID- 23133351 | hyperuricemia can lead to diseases like gout where uric acid is deposited into tissues, especially in the joints . |
| PubMedID- 25128519 | This finding supports the concept of distinctive mechanisms to account for hyperuricemia in patients with gout with reduced or normal uric acid excretion. |
| PubMedID- 23460805 | A sensitivity analysis restricting gout to individuals with hyperuricemia or self-reported gout medication use yielded virtually the same findings (supplemental table s5). |
| PubMedID- 24877124 | Febuxostat, a chemically engineered nonpurine selective inhibitor of xo, received approval in february 2009 from the food and drug administration for the chronic management of hyperuricemia in patients with gout . |
| PubMedID- 25971955 | Background: hyperuricemia can lead to gout, and may be a risk factor for cardiovascular events, hypertension, diabetes and renal disease. |
| PubMedID- 24287461 | It is suggested that hyperuricemia increases the risk of not only gout, but also other diseases as well, including hypertension, kidney disease, and metabolic syndrome 8. |
| PubMedID- 21264183 | The prototypical (xo) inhibitor, allopurinol, has been the cornerstone of the clinical management of gout and conditions associated with hyperuricemia for several decades. |
| PubMedID- 25928556 | Because low glomerular filtration rate (gfr) leads to hyperuricemia, ckd is associated with hyperuricemia and gout 4. |
| PubMedID- 21934587 | There appears to be a greater risk of developing gout with hyperuricemia, hypertension, and renal disease. |
Page: 1